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The rate of leprosy has been significantly reduced through
the implementation of intensified control strategies. Of
particular note is the free multidrug therapy (MDT) regimen
provided by the World Health Organization (WHO) since
1995, in which three standard first-line drugs, namely dia-
minodiphenylsulfone (dapsone), rifampicin, and clofazi-
mine, are available for use in multidrug regimens of fixed
duration.1 As a result, leprosy has been successfully elimi-
nated from 119 of 122 countries in 2010.2 Leprosy is
considered eliminated when the leprosy prevalence rate is
less than 1 in a population of 10,000. The enhanced global
strategy for further reducing the disease burden due to
leprosy (plan period: 2011e2015) has been carried out in
endemic countries.3 The prevalence of leprosy in the WHO
western Pacific region, where Taiwan is located, is 0.05 and
that of the southeast Asian region is 0.64 in the first quarter
of 2012.4
Leprosy is caused by Mycobacterium leprae, an acid-fast
bacillus bacterium. The bacterium has an incubation period
ranging from several months to several decades after
infection. Leprosy causes severe disfiguring skin sores and
nerve damage in the arms and legs. The skin becomes stiff
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patches. Sensory manifestations include paresthesia, pain,
and loss of feeling (numbness). In Taiwan, leprosy is a
notifiable disease and is mainly diagnosed by microscopic
analysis of skin smear, histological examination, and clin-
ical judgment. A comprehensive leprosy control program to
eliminate leprosy was implemented in Taiwan in the 1930s.
The first sanatorium was established in 1930 to quarantine
patients with leprosy. Nevertheless, leprosy cases have
been treated as outpatients since 2009 in five Taiwan
Centers for Disease Control (CDC), designated as integrated
medical service settings. Dapsone and MDT have been
prescribed since 1952 and 1983, respectively.5 According to
the Statistics of Communicable Diseases and Surveillance
Report issued by the Taiwan CDC, the prevalence of leprosy
decreased from 1.33/10,000 in 2002 to 0.50/10,000 in 2011
(Fig. 1A). The registered cases were 2,987 and 1,131 in 2002
and 2004, respectively. After the national census in 2004,
the prevalence rate decreased to 0.50 and leprosy was
considered eliminated in the country.Methods and results
Between 2002 and 2011, we confirmed 81 new leprosy
cases, with approximately five to 12 cases being reported
annually.6 There were 56 (69.1%) multibacillary cases, 21
(25.9%) paucibacillary cases, and four cases (4.9%) were not
determined. Females (50/81, 61.7%) are more vulnerable
than male (p Z 0.033). Geographically, 42 (51.9%), 26
(32.1%), 11 (13.6%), and two (2.5%) cases were reported
from the northern, southern, central, and eastern Taiwan,
respectively. Of the 81 cases reported, 37 (45.7%) were& Formosan Medical Association. All rights reserved.
Figure 1 (A) Annual imported cases among new cases,
registered cases, and prevalence. (B) Demographic character-
istics of imported and indigenous cases of leprosy in Taiwan,
2002e2011.
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(Fig. 1B). The majority (43/44, 97.7%) of the imported cases
originated from the southeast Asian countries, particularly
from Indonesia (32/44, 72.7%) (p < 0.001), which reported
20,023 new cases in 2011.4 In addition, of the total 425,660
foreign workers who entered Taiwan as of December 2011,
175,409 (41.2%) were from Indonesia. Among the 50 female
cases reported, 37 (74%) (p < 0.001) were imported cases
including 29 (58%) from Indonesia, four from Vietnam, three
from the Philippines, and one from China. Among the 31
male cases, seven (22.6%) were imported cases including
three from Indonesia, three from Thailand, and one from
Myanmar. The median ages of male indigenous and im-
ported cases were 60.5 years (range: 31e83 years) and 33
years (range: 24e60 years) (p Z 0.001), respectively,
whereas the median ages of females were 67 years (range:
45e81 years) and 27 years (range: 20e52 years) (p < 0.001),
respectively. We did not observe any leprosy case in in-
dividuals under the age of 19. The majority (42, 51.9%) of
cases reported were in the age group of 21e40 years
(p < 0.001), followed by 22 (27.2%) in the age group >60
years. Furthermore, 13 relapse indigenous cases were
notified in 2002e2011. Of the 13 cases, two were reac-
tivated after 5 years, one after 14 years, six after 35 years,
and four were unknown.
The National Reference Laboratory of Mycobacteriology
of the Taiwan CDC participates in national laboratory-based
surveillance for M. lepraedthis started in 2012 and involves
five sentinel hospitals in Taiwan. Because the majority of
patients with leprosy have a negative smear, the laboratory
established molecular assays for leprosy using a polymerase
chain reaction (PCR)-based analysis. The results of PCR
correlated well with biopsy findings. For M. leprae identifi-
cation, a primer set based on the M. leprae-specific repeti-
tive element was developed with a modified real-timeTaqMan PCR method.7 Of the 13 cases tested, two cases
were found to be resistant to dapsone with mutations in the
folP gene, and all cases were found to be susceptible to
rifampicin (the rpoB gene) or fluoroquinolone (the gyrA
gene) using nested PCR analysis and sequencing.8 Therefore,
minocycline was administered in addition to MDT for Case 1,
which showed a striking improvement in the following
several months. Case 2 is a relapse case with diabetes mel-
litus that initially responded poorly to the MDT regimen and
moxifloxacin was included in the prescription thereafter.
Discussion
Annual on-site health examination of cases, accurate
diagnosis, and proper treatment with MDT continue to
remain as the key elements in our control strategies. For
strengthened control of imported cases, the Enforcement
Rules of the Communicable Disease Control Act (imple-
mented in 2004) recommends that foreign workers are
required to provide a health certificate at entry, and to
have their health checkup done, including that for leprosy,
at the 6th, 18th, and 30th month during their stay in Taiwan.
Focused and sustained control measures are crucial for
reducing new and relapsed cases and preventing further
transmission of leprosy.
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